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ABSTRACT: Introduction: The adoption of multiparametric MRI 
(mpMRI) guided fusion biopsy is becoming an important  tool to 
improve the diagnostic yield in those suspected of having prostate 
cancer, especially for patients with suspicious lesion located at 
the anterior region that is uncommonly sampled at randomized 
biopsy. Methods: Herein we report a case of a man with persistent 
elevated PSA and a previous negative randomized prostate biopsy. 
His PSA was 8.1 ng/dL and a multiparametric MRI showed a 
2cm suspicious PIRADS-4 lesion located at the anterior region 
of the right transition zone at base and mid gland. A transrectal 
ultrasound/MRI (TRUS/mpMRI) fusion biopsy was performed 
and its pathologic report showed a Gleason 3+4 (ISUP II) that was 
present only in the fragments that sampled the suspected area at 
MRI. We review the role of mpMRI in the diagnosis of prostate 
cancer at rebiopsy.
Keywords: Prostate/pathology; Image-guided biopsy/methods; 
Prostatic neoplasms/diagnosis; Prostatic neoplasms/diagnostic 
imaging; Prostatic neoplasms/pathology.
RESUMO: Introdução: A adoção da biópsia de próstata 
guiada por fusão de imagens de ressonância magnética (RM) 
multiparamétrica está se tornando um método importante no 
diagnóstico do câncer de próstata, especialmente para aqueles com 
suspeita de lesão localizada na região anterior, que normalmente 
não é amostrada na biópsia randomizada. Métodos: Aqui 
relatamos um caso de homem com PSA persistentemente elevado 
e com uma biópsia randomizada anterior negativa. O PSA atual 
era de 8,1 ng / dL e a ressonância magnética multiparamétrica 
mostrou uma lesão suspeita PIRADS-4 de 2 cm localizada na 
região anterior da zona de transição direita na altura da base e 
terço médio da glândula. Foi realizada uma biópsia transretal 
guiada por fusão de imagens de ressonância multiparamétrica 
(TRUS / mpMRI) e o exame anatomopatológico mostrou a 
presença de adenocarcinoma escore de Gleason 3 + 4 (ISUP II) 
apenas nos fragmentos amostrados na área suspeita da mpMRI. 
Revisamos o papel da mpMRI no diagnóstico do câncer de 
próstata na rebiópsia.
Descritores: Próstata/patologia; Biópsia guiada por imagem/
métodos; Neoplasias da próstata; Neoplasias da próstata/
diagnóstico por imagem; Neoplasias da próstata/patologia.
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INTRODUCTION
Prostate cancer (PC) is the most common solid malignancy in western countries including 
Brazil1. The slow-growing nature, the heterogeneous 
clinical behavior and the long latency time of many cases 
highlight the need to predict which tumors will grow 
and spread beyond the prostate as compared to indolent 
tumors2. The diagnosis is usually established by transrectal 
ultrasound guided biopsy where a minimum of 12 cores are 
sampled in a randomized fashion under local anesthesia. 
The caveats with the 12-core biopsy are two-fold, there is 
a 30% false negative rate and an increase in the diagnosis 
rate of insignificant cancer3. 
The multiparametric magnetic resonance imaging 
(mpMRI) is a noninvasive method of identifying tumor 
location in the prostate as well as functional characteristics 
to predict tumor behavior and is employed in the diagnosis, 
staging and follow-up of patients after local treatment or 
active surveillance4. The accuracy of PC diagnosis based 
on mpMRI is higher when compared to TRUS, and one 
of its advantage is that Gleason score higher than 6 are 
preferentially visualized by this method4. The suspected 
lesions at mpMRI are classified according to the PIRADS-2 
criteria that range from 1-very low risk to 5-high risk of 
clinically significant PC (PCcs)5. Herein we report a case 
of a patient with persistent elevated PSA and a previous 
negative randomized prostate biopsy who underwent a 
transrectal ultrasound/mpMRI fusion biopsy. Additionally, 
we review the role of mpMRI in the diagnosis of PC at 
rebiopsy.
CASE REPORT
A 68-year-old white male patient came to a routine 
urological evaluation. No lower urinary tract symptoms 
or any other symptom was informed. He reported having 
systemic arterial hypertension on treatment with an ACE 
inhibitor. He denied any family history of PC.
Clinical examination of the external genitalia and 
the abdomen was normal. At the digital rectal examination, 
the prostate was enlarged to about 40g with a fibroelastic 
consistency and without suspected nodules. Laboratory 
tests (blood count and urine test strip) did not reveal any 
abnormalities. The serum PSA level was 5,7ng/dl and the 
free PSA was 14%. Further investigations were pursued 
by suprapubic ultrasound that showed signs of benign 
prostatic hyperplasia with a prostate volume of 44g, no 
post-voiding residual urine or upper urinary tract without 
abnormalities. A prostate biopsy was performed with a 
sampling of 12 fragments that showed no malignancy. 
Thus, he was advised to return in a year.
The patient returns after one year, with no voiding 
complaints for a new routine urological examination. The 
PSA was 8.15 ng/dl, free PSA 11% and again the DRE 
was unsuspicious. Because of a previous negative biopsy 
a mpMRI was required. It was performed in a high-field 
3-tesla unit without an endorectal coil and it showed a 
suspicious 2 cm PIRADS 4 lesion in the anterior region 
of the transitional zone at right base and mid gland. The 
lesion was ill delimited and had a hypointense signal at 
T2 and diffusion weighted ADC map sequences (Figure 
1). Subsequently a transrectal ultrasonography /MRI 
fusion-guided biopsy was performed and the pathologic 
report showed a Gleason score 3+4 (ISUP group 2) usual 
adenocarcinoma. The tumor was present only at the 4 cores 
that sampled the suspected area at MRI. The maximum core 
involvement was up to 55%.
DISCUSSION
The mpMRI has emerged as an important tool 
to more accurately determine the risk of significant 
disease at diagnosis because it provides an anatomical 
assessment which can determine the presence and location 
of the significant tumor4. The typical lesions have a 
hypointense signal on T2-weighted images; however other 
conditions may also have the same appearance such as 
androgen deprivation therapy, prostatitis, benign prostatic 
hyperplasia, previous radiotherapy. At the dynamic 
contrast-enhanced (DCE) phase the tumor shows a rapid 
contrast enhancement and wash-out, and at the DWI-ADC 
map the lesion is typically hypointense. The DCE and DWI 
imaging sequences provide more functional information 
and provide a comprehensive evaluation of suspected 
lesions and the joint analysis of the findings in these three 
parameters yields the PIRADS degree that is considered 
suspicious when it is ≥ 35.
One of the most interesting aspects is that suspicious 
changes in mpMRI are associated with a greater chance 
of PC with Gleason score ≥ 7. Thus, we could potentially 
reduce the diagnosis of indolent tumors if we biopsy only 
patients with suspected MRI. This test detects 95% of 
prostate tumors with GS > 7, when they present a tumor 
volume from 0.5 mL and have a negative predictive value 
of 80% - 98% for high risk tumors6.
In our case, the suspect area in the mpMRI was in 
the anterior transition zone around the midline, which is a 
area that is not usually sampled in systematic biopsy with 
12 fragments (Figure 1). It should be emphasized that at 
the ultrasound images there was no suspected hypoechoic 
lesion in this region. The biopsy of this region confirmed 
the diagnosis of PCcs which is in accordance with the 
literature data.
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Figure 1 – mpMRI showing a suspicious 2 cm PIRADS 4 lesion 
in the anterior region of the transitional zone at right base and mid 
gland. T2 axial (a), T2 sagital (b), and diffusion weighted DWI 
axial images (c)
The benefit of mpMRI in PC diagnosis was 
demonstrated by Sidiqqui et al.7, who prospectively 
compared 1,003 patients sequentially submitted to MRI-
guided biopsy versus USTR-guided biopsy with 12 
fragments of which 43% had a previous negative biopsy7. 
Similar PC detection rates were observed between the 
two methods 45.9% vs. 46.7%, but the biopsy guided by 
mpMRI detected 30% more high grade PC (173 vs. 122 
cases) and reduced by16% the detection of low grade 
tumors (213 vs. 258 cases (p<0,001). To diagnose a high-
grade PC, 30.7 fragments were required in the mpMRI-
guided biopsy and 100.8 in the USTR guided biopsy. When 
considered the tumors that USTR-guided biopsy did not 
detect, 60% of them were GS ≥ 7 while this rate fell to 1% 
in the mpMRI-guided biopsy group. The mpMRI-guided 
biopsy also showed greater concordance of the Gleason 
score of the biopsy vs. of the surgical specimen in the 170 
operated cases (p <0.05)7.
According to the literature, mpMRI-guided biopsy 
seems to have an advantage in patients with previous 
negative biopsy and persistence of suspected PC. A meta-
analysis of 16 studies, in which 1929 men with suspected 
mpMRI who underwent TRUS-guided biopsy versus 
mpMRI-guided biopsy, showed a significant increase in PC 
detection of 54% (relative sensitivity 1.54, 95% CI 1.05-
2.57 vs. 1.10, 95%, CI 1.00-1.22) in favor of mpMRI in 
patients with a history of previous negative biopsy and 10% 
in patients without previous biopsy8. The European and 
American Urological Association guidelines recommend 
that an mpMRI should be performed when a re-biopsy 
is indicated, and that at prostate biopsy 2 to 4 fragments 
must be sampled in the suspected mpMRI area plus the 12 
randomized fragments6,9.
Another interesting characteristic is the higher 
negative predictive value of a normal mpMRI for PCcs 
that is around 90-95%, making the exam a useful tool in 
determining whether a patient is a candidate for biopsy. 
Based on this finding some authors propose that a normal 
resonance be enough to not indicate a biopsy and that 
in the case of an altered MRI we could only sample the 
suspected lesion10.
Addressing the first question a multicenter 
prospective study (PROMIS trial) with 576 patients 
compared the performance of mpMRI-guided vs. TRUS-
guided prostate biopsy and observed negative predictive 
value for any cancer and for significant cancer of 76 and 
89%, respectively. It means that if one postpones the biopsy 
due a normal mpMRI this would lead to the loss of 24% of 
PC and 11% of PCcs cases11. Corroborating these results, 
a meta-analysis of 48 studies with 9613 found a negative 
predictive value of 82% for any PC and 88% for PCcs. 
Thus, again if a biopsy was contraindicated because of a 
normal mpMRI, about 12% of intermediate and high-risk 
tumors would not be diagnosed12. Current consensus also 
agrees that an mpMRI per se is not yet sufficient to postpone 
a biopsy in the presence of clinical suspicion6,9.
Addressing the question if we should sample only 
the suspected areas in patients with an altered mpMRI 
undergoing target biopsy, Borofsky et al.13, retrospectively 
evaluated 100 patients who had undergone mpMRI and 
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subsequent radical prostatectomy due PC diagnosis. The 
authors compared the pre-operative mpMRI findings with 
the whole-mount pathology slices report and found that 
of the 162 lesions, 136 (84%) were correctly identified 
with mpMRI but the size of 8 lesions was underestimated. 
Among the 26 (16%) lesions missed at MRI, GS was 
3+4 in 65%, 4+3 in 4%, 4+4 in 27%, and 4+5 in 4% of 
patients. On a per-patient basis, mpMRI depicted clinically 
important PC in 99 of 100 patients however at least one 
clinically important tumor was missed in 26 (26%) patients, 
and lesion size was underestimated in eight (8%) if only 
suspected areas were biopsied. They concluded that the 
limitation of mpMRI imaging is important, and new 
approaches to reduce this false-negative rate are needed13. 
Thus, despite the high negative predictive value of mpMRI, 
it is still early to abandon the systematic biopsy with 12 
fragments. Thus, as a rule, 12 randomized fragments must 
be sampled, plus 2 to 4 fragments directed to the suspected 
area in the mpMRI6,9.
There is no consensus as to whether mpMRI should 
be performed in patients already on the first biopsy, mainly 
because 2 meta-analysis studies based on retrospective 
studies have not shown an advantage in patients with 
no previous biopsy6. However, the first randomized, 
multicenter study that evaluated this situation was recently 
published. In this trial 500 men with a clinical suspicion 
of PC who had not undergone biopsy previously were 
assigned to undergo mpMRI, with or without targeted 
biopsy, or standard TRUS-guided biopsy14. Men in the 
mpMRI-targeted biopsy group underwent a targeted biopsy 
(without standard biopsy cores) if the MRI was suggestive 
of PC; and men whose MRI results were not suggestive 
of PC were not offered biopsy14. Regarding the overall PC 
detection there was no difference  46.8  vs. 47%, but the 
mpMRI arm showed a higher rate of PCcs diagnosis 38 
vs. 26% p=0.005 and lower rate of insignificant PC 9 vs 
22% p<0.0001. At the mpMRI arm 28% of patients had a 
PIRADS 1 - 2 and were not biopsied14. If the results of these 
trials are confirmed and the cost effectiveness studies also 
show advantage of the mpMRI in this scenario probably 
mpMRI will be also recommended for men with clinical 
suspicion of PC and no previous biopsy. The two critics to 
this study is that the patients with normal mpMRI did not 
underwent biopsy and based at the Promis trial results we 
know that 10% of PCcs will be missed if the biopsy is not 
performed11. Additionally, we must highlight that in 22% 
of cases there was a PIRADS assignment disagreement 
between the radiologist at the trial raising concern about the 
act of not offering biopsy if the PIRADS was less than 3.
There are three ways to perform the mpMRI guided 
biopsy. At the in-bore method the biopsy is performed 
inside the MRI device, it requires special material and the 
costs are higher. The advantage is that it would be a true 
real-time mpMRI-guided biopsy technique. The cognitive 
method does not require any special apparatus. In this 
method the images of the mpMRI are arranged next to the 
ultrasound device and the urologist cognitively samples 
the suspected area. The TRUS/mpMRI fusion biopsy 
requires ultrasound devices with special software that are 
fed with the images of the previously performed mpMRI 
and during the performance of the ultrasound the images of 
the mpMRI are coupled in real time with the images of the 
ultrasound and the suspected area is theoretically sampled 
with greater accuracy.
There is no clear evidence of superiority of one 
mpMRI-guided biopsy method over the other6,9. A meta-
analysis evaluated the results of the three methods in more 
than 3,500 patients in 39 studies15. Among the included 
studies 11 used the in-bore method, 17 employed the fusion 
guided method and 11 employed the cognitive biopsy. 
There was a significant advantage (p = 0.02) of in-bore 
compared with cognitive for overall PC detection. For 
overall PC detection there was no significant advantage 
of in-bore compared with fusion biopsy (p=0.13), and 
neither for fusion compared with cognitive (p=0.11). For 
PCcs detection there was no significant advantage of any 
technique of MRI-guided biopsy15.
In conclusion it is clear that the mpMRI has an 
important role in PC diagnosis. It is strongly recommended 
in patients with PC suspicious and previous negative biopsy 
and now we have some data also indicating advantage of the 
exam even in patients with no previous biopsy. The mpMRI 
has a high negative predictive value however it cannot 
avoid a systematic biopsy in patients with no prior biopsy. 
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